Theranostics refers to the use of precise diagnostic tests that reveal a specific molecular target on a tumour or other disease-causing entity.
Theranostics |
Theranostics is the use of
focused diagnostic testing in conjunction with tailored treatment. Companion
diagnostics, integrated medicine, Dx/Rx partnership, and pharmaco diagnostics
are other terms for it. The incorporation of theranostics into the patient care
plan (in the case of chosen disorders for which diagnostic tests are accessible
alongside related therapy) may result in tailored therapy, which may enhance
medical results even further.
Any disease pathophysiology
involves distinct biological pathways that may be addressed via diagnostic
testing. Diagnostic pictures of the specific molecule then identify the
existence of a certain mutation or receptors (in the case of cancer), which may
subsequently be targeted with therapeutic medicines. This method reduces trial
and error and might be utilised to provide patient-specific therapy at the
correct moment. Accurate dosage calibration and a finely tailored strategy
might be extremely beneficial in the treatment of chronic illnesses like
cancer.
The phrase Theranostics
is a blend of medicines and diagnostics. The word "theranostics"
refers to the use of one radioactive medication to detect (diagnose) and a
second radioactive drug to give therapy to treat the primary tumour and any
metastatic tumours. Tumor cells have a shell called a membrane; particular
proteins on the tumour cell membrane, such as the somatostatin receptor
(SSTR2), can serve as a target for cancer medicines. The radioactive diagnostic
medicine Ga-68 DOTATOC targets SSTR2. Ga-68 DOTATOC is injected into a
patient's vein and circulates throughout the circulation to all organs and
tissues. If the patient has a neuroendocrine tumor with SSTR2 on the tumor cell
membranes, the Ga-68 DOTATOC will bind to the SSTR2 and the tumor will light up
on a PET scan.
The development of novel
companion diagnostic tests to be used in conjunction with existing treatment
options is expected to drive global theranostics growth. Leading manufacturers
are working to bring novel companion diagnostic tests to market. In 2017,
Illumina, Inc. announced the launch of a U.S. Food & Drug Administration
(FDA) approved extended RAS panel for identifying patients suitable for
Vectibix (panitumumab) therapy of metastatic colorectal cancer.
Theranostics is the combining of
medicines and diagnostics in one package for image-guided therapy as well as
early treatment result prediction. There is a more extensive discussion of the
various kinds of nanomaterials, such as carbon-, polymer-, and metallic-based
nanoparticles, in terms of their capacity to execute the dual modality. The
basics of current therapeutic techniques such as photothermal therapy and
imaging instruments such as optical, magnetic resonance imaging, and ultrasound
are also presented. Researchers' basic techniques for various groups of
medicines and imaging technologies are also reviewed. Current advances in
theranostics, as well as various instances of other procedures that offer
promise for the future of medicine, are highlighted.
Comments
Post a Comment